09/11/2018 18:49:52

Adamas to Present at Three November Investor Conferences

EMERYVILLE, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the following three investor conferences:

  • Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 p.m. MST (4:50 p.m. EST)
  • Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018 at 11:00 a.m. EST
  • Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 8:00 a.m. EST

The presentations will be webcast live from the investor relations section of the Adamas website at https://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contacts:

Investors:

Ashleigh Barreto

Director, Corporate Communications and Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

Media:

Terri Clevenger

Continuum Health Communications

203-227-0209

tclevenger@continuumhealthcom.com

Adamas Pharmaceuticals Logo

Related content
12 Mar - 
Adamas Announces New Employment Inducement Grant
04 Mar - 
Adamas Reports Recent Achievements and Financial Result..
20 Feb - 
Adamas to Present at Two Upcoming Investor Conferences
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UKTW I²P Celebrates First Successful Year of UK-TW Science Research Cooperation
2
ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia
3
Reminder - Product Tanker, Crude Oil Tanker, LNG, LPG and Chemical Tankers Sector Panel Discussions With Major Shipping Company Executives
4
Invitation by Aperam S.A. to holders of its outstanding U.S.$300,000,000 0.625 per cent. Net Share Settled Convertible and/or Exchangeable Bonds due 2021 (ISIN XS1084287322) (the “Bonds”) convertible into common shares of Aperam S.A. to off
5
Philips expands its radiology solutions offering with advanced teleradiology services

Related stock quotes


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 March 2019 04:55:38
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB1 - 2019-03-26 05:55:38 - 2019-03-26 04:55:38 - 1000 - Website: OKAY